Skip to main content
. 2022 Feb 16;2022(2):CD007929. doi: 10.1002/14651858.CD007929.pub4

5.8. Analysis.

5.8

Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 8: Quality of Life ‐ Quality adjusted Progression‐free survival (QA‐PFS)